Pharmacokinetics and Target Attainment of SQ109 in Plasma and Human-Like Tuberculosis Lesions in Rabbits | Antimicrobial Agents and Chemotherapy
SQ109, a new drug lead for Chagas disease. - Abstract - Europe PMC
SQ109 mechanism of action The figure depicts stylized components of the... | Download Scientific Diagram
IJMS | Free Full-Text | Hydroxylation of Antitubercular Drug Candidate, SQ109, by Mycobacterial Cytochrome P450 | HTML
SQ109 = 98 HPLC 502487-67-4
SQ109 mechanism of action The figure depicts stylized components of the... | Download Scientific Diagram
Novel candidates in the clinical development pipeline for TB drug development and their synthetic approaches - Kumar - 2021 - Chemical Biology & Drug Design - Wiley Online Library
SQ109 Targets MmpL3, a Membrane Transporter of Trehalose Monomycolate Involved in Mycolic Acid Donation to the Cell Wall Core of Mycobacterium tuberculosis | Antimicrobial Agents and Chemotherapy
Tuberculosis Drugs and Mechanisms of Action | NIH: National Institute of Allergy and Infectious Diseases
SQ109 Targets MmpL3, a Membrane Transporter of Trehalose Monomycolate Involved in Mycolic Acid Donation to the Cell Wall Core of Mycobacterium tuberculosis | Antimicrobial Agents and Chemotherapy
SQ109 Targets MmpL3, a Membrane Transporter of Trehalose Monomycolate Involved in Mycolic Acid Donation to the Cell Wall Core of Mycobacterium tuberculosis | Antimicrobial Agents and Chemotherapy
Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. - Abstract - Europe PMC
Proposed sites of action of SQ109 and its analogues. MenA, MenG... | Download Scientific Diagram
SQ109 | Infectex
TB R&D Update: Tuberculosis drug, SQ109, targets multiple enzymes and could treat other diseases while preventing resistance | Working Group for New TB Drugs
Global tuberculosis drug development pipeline: the need and the reality - The Lancet
SQ109 | CAS:502487-67-4 | Antibiotic for treatment of pulmonary T | High Purity | Manufacturer BioCrick
Hydroxylation of antitubercular drug candidate, SQ109, by mycobacterial cytochrome P450 | bioRxiv
Insights on how the Mycobacterium tuberculosis heme uptake pathway can be used as a drug target | Future Medicinal Chemistry
Structure–activity relationship of SQ-109. | Download Scientific Diagram
Strategies towards the synthesis of anti-tuberculosis drugs - Organic & Biomolecular Chemistry (RSC Publishing) DOI:10.1039/C9OB00817A
Tuberculosis Drugs and Mechanisms of Action | NIH: National Institute of Allergy and Infectious Diseases
Multitarget Drug Discovery for Tuberculosis and Other Infectious Diseases | Journal of Medicinal Chemistry
New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects - The Lancet Infectious Diseases
Biomedicines | Free Full-Text | In Vivo Efficacy of SQ109 against Leishmania donovani, Trypanosoma spp. and Toxoplasma gondii and In Vitro Activity of SQ109 Metabolites | HTML
IJMS | Free Full-Text | Hydroxylation of Antitubercular Drug Candidate, SQ109, by Mycobacterial Cytochrome P450 | HTML
